Clinical trial · Interventional
Tomotherapy in Postsurgery Recurrent Carcinoma Cervix
Phase II Study Evaluating the Role of Tomotherapy- Based Intensity Modulated Radiotherapy and Brachytherapy in Postsurgery Recurrent Carcinoma Cervix
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy is the most appropriate treatment for postoperative recurrent carcinoma cervix. However it is technically difficult to deliver adequate doses of RT due to presence of small intestines in the radiation area; thus disease control rates are poor and complication rates are high with conventional radiotherapy. Use of IMRT and brachytherapy for these cases allows for increasing dose to the tumor while sparing normal structures. It is expected that the use of a combination of IMRT \& brachytherapy will achieve higher disease control rates and decrease the complication rates.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Postsurgery Recurrent Carcinoma Cervix | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the utility of intensity-modulated radiotherapy (IMRT) in delivering dose escalated radiotherapy in postoperative recurrent cases of carcinoma cervix, in terms of local control
- timeFrame
- 3 Years
- description
- Progression free survival of all patients
Secondary outcomes (1)
- measure
- To study the late toxicities associated with this treatment
- timeFrame
- 3 Years
- description
- Side effects of radiotherapy and chemotherapy will be recorded at baseline, during treatment, at 6 and 12 months and annually thereafter according to the RTOG scales
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: . Only histologically proven postoperative recurrence of squamous carcinoma of cervix following hysterectomy \>3 months without adjuvant treatment * Patients below 65 years of age and with KPS \>70%. * Patients with disease confined to the pelvis, based on CT/MRI/PET Scan * Normal ECG and cardiovascular system * Normal hematological parameters * Normal renal and liver function tests Exclusion Criteria: * Previous chemotherapy or radiotherapy to the pelvis * Pelvic LN \>3cm in size * Presence of disease outside the pelvis (Paraortic nodes, distant metastasis) * Bilateral hydronephrosis * Co-morbid conditions like uncontrolled Diabetes Mellitus or medical renal disease * Medical or Psychological condition that would preclude treatment * Patient unreliable for treatment and follow-up.
References
Publications (0)
Data not yet available